BioCryst Pharmaceuticals, Inc. (BCRX) Given Consensus Recommendation of “Hold” by Brokerages
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been assigned a consensus rating of “Hold” from the thirteen brokerages that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $9.14.
BCRX has been the subject of several research reports. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, November 8th. Royal Bank of Canada initiated coverage on BioCryst Pharmaceuticals in a report on Thursday, September 14th. They issued a “sector perform” rating and a $6.00 target price for the company. Finally, Barclays initiated coverage on BioCryst Pharmaceuticals in a report on Wednesday, December 20th. They issued an “equal weight” rating and a $6.00 target price for the company.
BioCryst Pharmaceuticals (BCRX) traded down $0.06 during trading on Friday, hitting $5.76. The stock had a trading volume of 1,399,900 shares, compared to its average volume of 2,021,167. BioCryst Pharmaceuticals has a fifty-two week low of $3.95 and a fifty-two week high of $9.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.53 and a quick ratio of 2.53. The stock has a market cap of $557.95, a P/E ratio of -9.00 and a beta of 3.05.
In related news, CMO William P. Sheridan sold 64,310 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $4.72, for a total value of $303,543.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 5.80% of the stock is currently owned by insiders.
A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in BioCryst Pharmaceuticals by 19.9% in the 2nd quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock valued at $33,404,000 after acquiring an additional 996,052 shares during the period. RA Capital Management LLC increased its position in BioCryst Pharmaceuticals by 47.9% in the 2nd quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock valued at $28,702,000 after acquiring an additional 1,672,447 shares during the period. Janus Henderson Group PLC acquired a new position in BioCryst Pharmaceuticals in the 3rd quarter valued at about $23,762,000. State Street Corp increased its position in BioCryst Pharmaceuticals by 72.0% in the 2nd quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock valued at $21,736,000 after acquiring an additional 1,636,909 shares during the period. Finally, VHCP Management II LLC increased its position in BioCryst Pharmaceuticals by 27.9% in the 3rd quarter. VHCP Management II LLC now owns 3,165,457 shares of the biotechnology company’s stock valued at $16,587,000 after acquiring an additional 690,290 shares during the period. Hedge funds and other institutional investors own 84.69% of the company’s stock.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.